Selcia Adds Director of Discovery Role

John Davis has been appointed to the newly created role of director of discovery at Selcia Ltd. Mr. Davis joins the company from Convergence Pharmaceuticals, where he served as head of biology and was a co-founder of the company.
 
Mr. Davis’ research has focused on cardiovascular, oncology and CNS disorders. He gained 20 years of drug discovery experience at SmithKline Beecham and GlaxoSmithKline across range of target classes including ion channels, GPCRs, kinases and proteases. He was responsible for the discovery of 11 small molecule and biologic development candidates and the preclinical pharmacology supporting two assets.
 
At GSK he was director of neurodegeneration research, a director of discovery technologies and director of biology for pain and epilepsy research, and also managed several large collaborations with universities.
 
Dr. Hans Fliri, chairman and chief executive officer of Selcia, said, “We are delighted that John has joined Selcia, his extensive drug discovery expertise will be a tremendous asset to our business. We have an ambitious plan to grow and further develop Selcia’s integrated drug discovery service. John’s knowledge of the international pharmaceutical and biotechnology industries will undoubtedly help us achieve that goal. ”